New hope for lymphoma patients who Can't get a transplant

NCT ID NCT05626322

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times

Summary

This study tested a new three-drug combination for people with a type of blood cancer called diffuse large B-cell lymphoma that came back or didn't respond to prior treatment. Participants could not have a stem cell transplant or CAR-T therapy. The goal was to find a safe and effective dose of the new drug, maplirpacept, when given with two other medicines. The study was stopped early after enrolling only 6 people.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dong-A University Hospital

Busan, Pusan-kwangyǒkshi, 49201, South Korea
Lifespan Cancer Institute

Providence, Rhode Island, 02903, United States
Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, 70809, United States
Seoul National University Hospital

Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea
The Miriam Hospital

Providence, Rhode Island, 02906, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
Yamagata University Hospital

Yamagata, 990-9585, Japan

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B CELL LYMPHOMA